Biovian and Lokon Pharma are featured in Biopharma Dealmakers September issue. The article “Manufacturing the next generation of cancer immunotherapeutics”, describes the history and currents state of Lokon Pharma’s proprietary LOAd technology.
This immunostimulatory gene therapy, delivered in oncolytic adenoviruses, are poised to enter pivotal trials for cancer. Biovian Oy is manufacturing Lokon’s immunotherapeutics for these trials and beyond.
“The complexity of LOAd703 means that Lokon had to find a CDMO with the technical expertise to not only handle the different aspects of manufacturing LOAd703, but also the capacity to perform all the necessary steps in house and, looking beyond clinical trials, to manufacture LOAd703 as a commercial product. “
“In searching for a CDMO that could deliver on these goals, Lokon found a perfect partner in Finnish CDMO Biovian.”
Manufacturing the next generation of cancer immunotherapeuticsDownload